SEHK:1952Biotechs
Everest Medicines (SEHK:1952) Is Down 7.0% After Striking First Ophthalmology Deal With Visara Inc
On October 28, 2025, Everest Medicines Limited announced it had entered into an exclusive licensing agreement with Visara Inc. to develop, manufacture, and commercialize VIS-101, a novel bifunctional biologic for wet age-related macular degeneration, diabetic macular edema, and retinal vein occlusion, in Greater China, Singapore, South Korea, and select Southeast Asian countries, with upfront, milestone, and royalty payments totaling up to US$89 million plus additional expenses.
This...